- Resistance to first-line antituberculosis drugs.
| Drugs | 2015 | 2016 | 2017 | 2018 | 2019 | P-values |
|---|---|---|---|---|---|---|
| Isoniazid | ||||||
| Sensitive | 89.5 | 87.2 | 91.3 | 90.5 | 93.6 | |
| Intermediate | 3.2 | 2.6 | 1.5 | 1.6 | 1.3 | |
| Resistance | 7.3 | 10.3 | 7.3 | 7.9 | 5.1 | <0.001* |
| Pyrazinamide | ||||||
| Sensitive | 90.7 | 88.8 | 90.5 | 93.4 | 91.1 | |
| Intermediate | 3.4 | 2.6 | 2.2 | 2.1 | 2.3 | |
| Resistance | 6.0 | 8.6 | 7.3 | 4.5 | 6.6 | 0.055 |
| Ethambutol | ||||||
| Sensitive | 94.1 | 93.5 | 96.1 | 96.5 | 97.2 | |
| Intermediate | 3.1 | 2.8 | 1.5 | 1.7 | 1.2 | |
| Resistance | 2.8 | 3.7 | 2.5 | 1.8 | 1.6 | 0.002* |
| Rifampicin | ||||||
| Sensitive | 94.1 | 92.4 | 93.9 | 93.8 | 96.2 | |
| Intermediate | 1.8 | 2.1 | 1.4 | 1.5 | 1.2 | |
| Resistance | 4.0 | 5.5 | 4.7 | 4.7 | 2.6 | 0.067 |
| Streptomycin | ||||||
| Sensitive | 86.9 | 83.5 | 90.9 | 91.3 | 92.8 | |
| Intermediate | 3.3 | 2.9 | 1.6 | 1.7 | 1.5 | |
| Resistance | 9.8 | 13.6 | 7.5 | 6.9 | 5.7 | <0.001* |
| Overall resistance patterns | ||||||
| Drug-susceptible | 88.1 | 85.8 | 89.6 | 89.7 | 92.7 | <0.001* |
| Monoresistance‡ | 13.6 | 17.0 | 12.5 | 10.6 | 13.2 | 0.001* |
| PDR | 4.7 | 5.7 | 4.0 | 2.2 | 1.9 | <0.001* |
| MDR | 4.4 | 5.7 | 4.0 | 4.4 | 2.4 | 0.008* |
| XDR§ | - | - | - | - | - | |
Values are presented as precentages (%).
PDR: polydrug resistance, MDR: multidrug resistance, XDR: extensive drug resistance
↵* Statistically significant difference between the years (p<0.05) and Chi-square test was used.
↵§ Data regarding second-line injectable drugs (capreomycin, kanamycin, and amikacin) were not available to establish XDR.
↵‡ The calculation of monoresistance is not accurate, because all drugs were not tested for all the included patients; hence, the absence of result was assumed to be absence of resistance.